Anebulo Pharmaceuticals (ANEB) Competitors $2.58 +0.08 (+3.20%) Closing price 04:00 PM EasternExtended Trading$2.58 +0.00 (+0.19%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANEB vs. YMAB, AQST, RGNX, VIGL, ATXS, CAPR, NBTX, AURA, ESPR, and FULCShould you be buying Anebulo Pharmaceuticals stock or one of its competitors? The main competitors of Anebulo Pharmaceuticals include Y-mAbs Therapeutics (YMAB), Aquestive Therapeutics (AQST), REGENXBIO (RGNX), Vigil Neuroscience (VIGL), Astria Therapeutics (ATXS), Capricor Therapeutics (CAPR), Nanobiotix (NBTX), Aura Biosciences (AURA), Esperion Therapeutics (ESPR), and Fulcrum Therapeutics (FULC). These companies are all part of the "pharmaceutical products" industry. Anebulo Pharmaceuticals vs. Its Competitors Y-mAbs Therapeutics Aquestive Therapeutics REGENXBIO Vigil Neuroscience Astria Therapeutics Capricor Therapeutics Nanobiotix Aura Biosciences Esperion Therapeutics Fulcrum Therapeutics Anebulo Pharmaceuticals (NASDAQ:ANEB) and Y-mAbs Therapeutics (NASDAQ:YMAB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations and risk. Do insiders & institutionals believe in ANEB or YMAB? 28.4% of Anebulo Pharmaceuticals shares are held by institutional investors. Comparatively, 70.9% of Y-mAbs Therapeutics shares are held by institutional investors. 80.6% of Anebulo Pharmaceuticals shares are held by company insiders. Comparatively, 19.7% of Y-mAbs Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts prefer ANEB or YMAB? Anebulo Pharmaceuticals presently has a consensus price target of $5.50, indicating a potential upside of 113.18%. Y-mAbs Therapeutics has a consensus price target of $9.62, indicating a potential upside of 12.94%. Given Anebulo Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Anebulo Pharmaceuticals is more favorable than Y-mAbs Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anebulo Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Y-mAbs Therapeutics 2 Sell rating(s) 8 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80 Does the media refer more to ANEB or YMAB? In the previous week, Anebulo Pharmaceuticals had 3 more articles in the media than Y-mAbs Therapeutics. MarketBeat recorded 5 mentions for Anebulo Pharmaceuticals and 2 mentions for Y-mAbs Therapeutics. Y-mAbs Therapeutics' average media sentiment score of 0.91 beat Anebulo Pharmaceuticals' score of 0.76 indicating that Y-mAbs Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anebulo Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Y-mAbs Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, ANEB or YMAB? Anebulo Pharmaceuticals has a beta of -0.88, meaning that its share price is 188% less volatile than the S&P 500. Comparatively, Y-mAbs Therapeutics has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500. Which has preferable valuation and earnings, ANEB or YMAB? Anebulo Pharmaceuticals has higher earnings, but lower revenue than Y-mAbs Therapeutics. Y-mAbs Therapeutics is trading at a lower price-to-earnings ratio than Anebulo Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnebulo PharmaceuticalsN/AN/A-$8.20M-$0.26-9.92Y-mAbs Therapeutics$87.68M4.42-$29.67M-$0.50-17.04 Is ANEB or YMAB more profitable? Anebulo Pharmaceuticals has a net margin of 0.00% compared to Y-mAbs Therapeutics' net margin of -26.03%. Y-mAbs Therapeutics' return on equity of -24.60% beat Anebulo Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Anebulo PharmaceuticalsN/A -90.11% -84.53% Y-mAbs Therapeutics -26.03%-24.60%-18.89% SummaryAnebulo Pharmaceuticals beats Y-mAbs Therapeutics on 9 of the 15 factors compared between the two stocks. Get Anebulo Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ANEB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANEB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANEB vs. The Competition Export to ExcelMetricAnebulo PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$105.99M$3.12B$5.70B$9.79BDividend YieldN/A2.21%3.77%4.10%P/E Ratio-9.9220.7930.8625.27Price / SalesN/A232.09403.8888.61Price / CashN/A41.5625.2228.45Price / Book17.209.749.516.00Net Income-$8.20M-$54.74M$3.26B$265.34M7 Day Performance8.86%8.13%4.50%2.79%1 Month Performance57.32%7.74%5.22%1.51%1 Year Performance30.30%18.08%31.92%25.40% Anebulo Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANEBAnebulo Pharmaceuticals2.2333 of 5 stars$2.58+3.2%$5.50+113.2%+26.3%$105.99MN/A-9.924YMABY-mAbs Therapeutics2.6763 of 5 stars$8.52-0.1%$11.16+31.1%-30.4%$385.56M$87.68M-17.03150Positive NewsAQSTAquestive Therapeutics2.1083 of 5 stars$3.90+0.9%$10.14+160.4%-3.1%$385.50M$57.56M-6.58160Earnings ReportAnalyst RevisionRGNXREGENXBIO4.2652 of 5 stars$7.60+1.9%$28.38+273.4%-28.0%$384.89M$83.33M-2.22370VIGLVigil Neuroscience3.2872 of 5 stars$8.05flat$10.80+34.2%N/A$383.91MN/A-3.9340ATXSAstria Therapeutics2.6927 of 5 stars$6.58-1.5%$29.00+340.7%-38.7%$370.18MN/A-3.5130News CoverageEarnings ReportAnalyst RevisionCAPRCapricor Therapeutics3.0245 of 5 stars$7.86+0.5%$22.56+187.0%+101.0%$356.12M$22.27M-5.49101Trending NewsEarnings ReportAnalyst RevisionGap DownNBTXNanobiotix0.8208 of 5 stars$7.37+0.3%$8.00+8.5%+59.8%$353.32M$39.18M0.00100News CoverageShort Interest ↑Gap UpAURAAura Biosciences1.6563 of 5 stars$7.00+2.3%$22.00+214.5%-14.7%$349.88MN/A-3.6650News CoverageEarnings ReportAnalyst RevisionESPREsperion Therapeutics4.0321 of 5 stars$1.77-4.3%$7.00+296.6%+4.6%$349.82M$332.31M-3.60200Analyst UpgradeFULCFulcrum Therapeutics1.3605 of 5 stars$6.42+1.2%$7.57+18.0%-26.2%$346.72M$80M-5.25100 Related Companies and Tools Related Companies Y-mAbs Therapeutics Alternatives Aquestive Therapeutics Alternatives REGENXBIO Alternatives Vigil Neuroscience Alternatives Astria Therapeutics Alternatives Capricor Therapeutics Alternatives Nanobiotix Alternatives Aura Biosciences Alternatives Esperion Therapeutics Alternatives Fulcrum Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANEB) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredGENIUS Act: Cancel Your Money?They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—no...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anebulo Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anebulo Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access